RxDoctor Payments Data

Bradley Why

Psychiatric/Mental Health · Newark, DENPI 1871821322

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,800in general payments, 2019–2025

Across 369 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$908
  • AbbVie$902
  • Alkermes, Inc.$650
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$534
  • Johnson & Johnson$444
  • Takeda Pharmaceuticals U.S.A., Inc.$405
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$5,66498%
  • Education$1362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,800 in reported general payments places this provider in the 95th percentile of 177 psychiatric/mental health providers in Delaware.

See all psychiatric/mental health providers in Delaware

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$117,340
Lurasidone Hcl19$21,031
TrintellixVortioxetine Hydrobromide32$16,259
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$3,049
Fluoxetine Hcl57$1,714
Bupropion XlBupropion Hcl26$1,252
Duloxetine Hcl54$1,148
Quetiapine Fumarate33$848
Aripiprazole15$730
Olanzapine39$691
Alprazolam38$581
Clonazepam38$521
Gabapentin28$414
Bupropion Hcl SrBupropion Hcl13$330
Trazodone Hcl33$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$164$117,34012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$405$16,25932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 psychiatric/mental health providers in Delaware.

Other psychiatric/mental health in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →